38873-82-4

Usage

Uses

Used in Pharmaceutical Industry:
15(R)-PROSTAGLANDIN E2 is used as a pharmaceutical agent for its oxytocic and abortifacient properties. It is utilized in the induction of labor and the management of postpartum hemorrhage due to its ability to stimulate uterine contractions.
Used in Research Applications:
In the field of research, 15(R)-PROSTAGLANDIN E2 is used as a research tool to study the biological effects and mechanisms of action of prostaglandins. This helps in understanding their role in various physiological processes and potential therapeutic applications.
Used in Cosmetic Industry:
Although not explicitly mentioned in the provided materials, 15(R)-PROSTAGLANDIN E2 may also have potential applications in the cosmetic industry, where prostaglandins are sometimes used for their anti-inflammatory and skin-regenerative properties. However, further research and validation are required to confirm its use in this industry.

Upstream product

• 303015-42-1 ethyl (5Z,8R,9R,11S,12S,13E,15R)-9-acetoxy-11,15-bis-(tert-butyldimethylsilyloxy)prosta-5,13-dienoate 
• 303015-43-2 (5Z,8R,9R,11S,12S,13E,15R)-11,15-bis-(tert-butyldimethylsilyloxy)-9-hydroxyprosta-5,13-dienoic acid 
• 214748-78-4 (Z)-7-[(1R,2S,3S,5R)-5-Acetoxy-3-hydroxy-2-((E)-(R)-3-hydroxy-oct-1-enyl)-cyclopentyl]-hept-5-enoic acid ethyl ester 
• 303015-41-0 (5Z,8R,9R,11S,12S,13E,15R)-11,15-bis-(tert-butyldimethylsilyloxy)-9-oxoprosta-5,13-dienoic acid 
• 851542-07-9 (Z)-7-{(1R,2R,3R,5S)-2-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-hydroxy-3-triethylsilanyloxy-cyclopentyl}-hept-5-enoic acid methyl ester 
• 851542-06-8 (2R,3aR,4R,5R,6aS)-4-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-triethylsilanyloxy-hexahydro-cyclopenta[b]furan-2-ol 
• 851542-05-7 (1S,2R,3R,4R)-3-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-2-(2-hydroxy-ethyl)-4-triethylsilanyloxy-cyclopentanol 
• 851542-04-6 (3aR,4R,5R,6aS)-4-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-triethylsilanyloxy-hexahydro-cyclopenta[b]furan-2-one 
• 851542-08-0 (Z)-7-{(1R,2R,3R,5S)-2-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-3,5-dihydroxy-cyclopentyl}-hept-5-enoic acid methyl ester 
• 851542-03-5 Benzoic acid (3aR,4R,5R,6aS)-4-[(E)-(R)-3-(tert-butyl-dimethyl-silanyloxy)-oct-1-enyl]-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 137625-91-3 (3aR,4R,5R,6aS)-4-[(E)-(R)-3-(tert-Butyl-dimethyl-silanyloxy)-oct-1-enyl]-5-hydroxy-hexahydro-cyclopenta[b]furan-2-one 
• 40834-86-4 (3aR,4R,5R,6aS)-benzoic acid 2-oxo-4-[(1E)-3-oxo-oct-1-enyl]-hexahydro-cyclopenta[b]furan-5-yl ester 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 51705-58-9 [3aR,4R(1E,3R),5R,6aS]-5-benzoyloxy-4-(3-hydroxyocten-1-yl)-hexahydro-2H-cyclopenta[b]furan-2-one 

Downstream Products

• 23453-26-1 (+/-)-prostaglandin E₂ methyl ester 

Relevant academic research and scientific papers

Synthesis of 15R-PGD2: A potential DP2 receptor agonist

The first total synthesis of 15R-PGD2 3 was accomplished. The approach used in this report is also an efficient method to produce 15R-PGE 2. 15R-PGD2, a potential DP2 receptor agonist, could be an important novel tool for defining the role of this receptor in inflammatory diseases.

Preparation of ent-prostaglandin E2

The enantiomeric prostaglandins, exemplified by ent-PGE2, are apparently produced in vivo by the nonenzymatic oxidation of arachidonic acid. To assess the physiological activity of ent-PGE2, it was necessary to prepare it by total sy

Racemic fluoro-substituted PGF2 α analogs

This invention is racemic PGE2, racemic PGF2α, racemic PGF2β, racemic PGA2, racemic PGB2, analogs of those, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibiton of platelet aggregation, increase of nasal patency, abortion, and wound healing.

Racemic prostaglandins of the 2-series and analogs thereof

This invention is racemic PGE 2, racemic PGF 2 α, racemic PGF 2 β, racemic PGA 2, racemic PGB 2, analogs of those, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, abortion, and wound healing.

Racemic prostaglandins of the 2-series and analogs thereof

This invention is racemic PGE2, racemic PGF2α, racemic PGF2β , racemic PGA2, racemic PGB2, analogs of those, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, abortion, and wound healing.

Enzymatic preparation and purification of prostaglandin E2.

An enzymatic system has been developed for the production of prostaglandin E(2) (PGE(2)) from arachidonic acid by extracts of sheep seminal vesicular glands. The presence of glutathione insures high yields. A new procedure for the purification of PGE(2) was also developed, based on the dialysis of the biosynthesized product at pH 8 and extraction of the dialysate at pH 3 with chloroform. This procedure routinely gives yields of PGE(2) of 25-37% (from arachidonic acid) with a purity of 90-100%. Additional analytical proof of the identity of PGE(2) was provided by physicochemical characteristics of the crystalline thiosemicarbazide derivative, which can be readily prepared under mild conditions.